Range of Manual and Automated Equipment and Consumables Support Productivity Advances in Microbiology Labs
WALTHAM, Mass., Jul 18, 2011 (BUSINESS WIRE) -- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that it has acquired TREK Diagnostic Systems, a global provider of microbiology solutions, including blood culture, microorganism identification and antibiotic susceptibility testing (AST) products, from Magellan Biosciences. Based near Cleveland, Ohio, the company had full year revenue in 2010 of $34 million and has 150 employees.
"The range of products manufactured by TREK ideally complements our existing portfolio of microbiological testing technologies," said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. "Advances in automation and the development of more rapid and reliable tests enable us to provide our customers with improvements in productivity and efficiency that are critical when responding to increasingly complex microbiological threats to human health."
TREK Diagnostic Systems currently serves pharmaceutical and clinical laboratory markets and will be integrated into Thermo Fisher's Analytical Technologies Segment.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of nearly $11 billion, we have approximately 37,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit http://www.thermofisher.com.
SOURCE: Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
Media Contact Information:
Ron O'Brien, 781-622-1242
Investor Contact Information:
Ken Apicerno, 781-622-1294